Plasma Markers of Inflammation Linked to Clinical Progression and Decline During Preclinical AD

Research output: Contribution to journalArticle

Abstract

Objective: To examine the prospective association between blood biomarkers of immune functioning (i.e., innate immune activation, adaptive immunity, and inflammation) and subsequent cognitive decline and clinical progression to mild cognitive impairment (MCI) in cognitively normal individuals. Methods: The BIOCARD study is an observational cohort study of N = 191 initially cognitively healthy participants (mean age 65.2 years). Blood plasma samples were assayed for markers of chronic inflammation (TNFR1, IL-6), adaptive immunity (CD25), and innate immune activation (CD14 and CD163). Participants were followed annually for ongoing clinical assessment and cognitive testing for up to 7.3 years. Primary study outcomes were progression to MCI and cognitive change over time, as measured by a global factor score encompassing multiple cognitive domains. Results: Higher levels of plasma TNFR1 were associated with greater risk of progression from normal cognition to MCI (HR: 3.27; 95% confidence interval, CI: 1.27, 8.40). Elevated levels of TNFR1 were also associated with steeper rate of cognitive decline on follow-up but not with baseline cognitive performance. Baseline IL-6 levels and markers of innate and adaptive immune activation showed no relationship with MCI risk or cognitive decline. Conclusion: Inflammation, mediated by TNF signaling, may play a selective role in the early phase of AD. Accordingly, plasma TNFR1 may facilitate improved prediction of disease progression for individuals in the preclinical stage of AD.

Original languageEnglish (US)
Article number229
JournalFrontiers in Aging Neuroscience
Volume11
DOIs
StatePublished - Sep 6 2019

Fingerprint

Receptors, Tumor Necrosis Factor, Type I
Inflammation
Adaptive Immunity
Interleukin-6
Cognitive Dysfunction
Cognition
Observational Studies
Disease Progression
Healthy Volunteers
Cohort Studies
Biomarkers
Outcome Assessment (Health Care)
Confidence Intervals

Keywords

  • biomarkers
  • cognitive decline
  • cytokines
  • inflammation
  • preclinical AD
  • TNFR1

ASJC Scopus subject areas

  • Aging
  • Cognitive Neuroscience

Cite this

@article{dd80ae2a1d2b47f48afc257c71b42544,
title = "Plasma Markers of Inflammation Linked to Clinical Progression and Decline During Preclinical AD",
abstract = "Objective: To examine the prospective association between blood biomarkers of immune functioning (i.e., innate immune activation, adaptive immunity, and inflammation) and subsequent cognitive decline and clinical progression to mild cognitive impairment (MCI) in cognitively normal individuals. Methods: The BIOCARD study is an observational cohort study of N = 191 initially cognitively healthy participants (mean age 65.2 years). Blood plasma samples were assayed for markers of chronic inflammation (TNFR1, IL-6), adaptive immunity (CD25), and innate immune activation (CD14 and CD163). Participants were followed annually for ongoing clinical assessment and cognitive testing for up to 7.3 years. Primary study outcomes were progression to MCI and cognitive change over time, as measured by a global factor score encompassing multiple cognitive domains. Results: Higher levels of plasma TNFR1 were associated with greater risk of progression from normal cognition to MCI (HR: 3.27; 95{\%} confidence interval, CI: 1.27, 8.40). Elevated levels of TNFR1 were also associated with steeper rate of cognitive decline on follow-up but not with baseline cognitive performance. Baseline IL-6 levels and markers of innate and adaptive immune activation showed no relationship with MCI risk or cognitive decline. Conclusion: Inflammation, mediated by TNF signaling, may play a selective role in the early phase of AD. Accordingly, plasma TNFR1 may facilitate improved prediction of disease progression for individuals in the preclinical stage of AD.",
keywords = "biomarkers, cognitive decline, cytokines, inflammation, preclinical AD, TNFR1",
author = "Gross, {Alden L} and Keenan Walker and Moghekar, {Abhay R} and Corinne Pettigrew and Anja Soldan and Marilyn Albert and Walston, {Jeremy D}",
year = "2019",
month = "9",
day = "6",
doi = "10.3389/fnagi.2019.00229",
language = "English (US)",
volume = "11",
journal = "Frontiers in Aging Neuroscience",
issn = "1663-4365",
publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - Plasma Markers of Inflammation Linked to Clinical Progression and Decline During Preclinical AD

AU - Gross, Alden L

AU - Walker, Keenan

AU - Moghekar, Abhay R

AU - Pettigrew, Corinne

AU - Soldan, Anja

AU - Albert, Marilyn

AU - Walston, Jeremy D

PY - 2019/9/6

Y1 - 2019/9/6

N2 - Objective: To examine the prospective association between blood biomarkers of immune functioning (i.e., innate immune activation, adaptive immunity, and inflammation) and subsequent cognitive decline and clinical progression to mild cognitive impairment (MCI) in cognitively normal individuals. Methods: The BIOCARD study is an observational cohort study of N = 191 initially cognitively healthy participants (mean age 65.2 years). Blood plasma samples were assayed for markers of chronic inflammation (TNFR1, IL-6), adaptive immunity (CD25), and innate immune activation (CD14 and CD163). Participants were followed annually for ongoing clinical assessment and cognitive testing for up to 7.3 years. Primary study outcomes were progression to MCI and cognitive change over time, as measured by a global factor score encompassing multiple cognitive domains. Results: Higher levels of plasma TNFR1 were associated with greater risk of progression from normal cognition to MCI (HR: 3.27; 95% confidence interval, CI: 1.27, 8.40). Elevated levels of TNFR1 were also associated with steeper rate of cognitive decline on follow-up but not with baseline cognitive performance. Baseline IL-6 levels and markers of innate and adaptive immune activation showed no relationship with MCI risk or cognitive decline. Conclusion: Inflammation, mediated by TNF signaling, may play a selective role in the early phase of AD. Accordingly, plasma TNFR1 may facilitate improved prediction of disease progression for individuals in the preclinical stage of AD.

AB - Objective: To examine the prospective association between blood biomarkers of immune functioning (i.e., innate immune activation, adaptive immunity, and inflammation) and subsequent cognitive decline and clinical progression to mild cognitive impairment (MCI) in cognitively normal individuals. Methods: The BIOCARD study is an observational cohort study of N = 191 initially cognitively healthy participants (mean age 65.2 years). Blood plasma samples were assayed for markers of chronic inflammation (TNFR1, IL-6), adaptive immunity (CD25), and innate immune activation (CD14 and CD163). Participants were followed annually for ongoing clinical assessment and cognitive testing for up to 7.3 years. Primary study outcomes were progression to MCI and cognitive change over time, as measured by a global factor score encompassing multiple cognitive domains. Results: Higher levels of plasma TNFR1 were associated with greater risk of progression from normal cognition to MCI (HR: 3.27; 95% confidence interval, CI: 1.27, 8.40). Elevated levels of TNFR1 were also associated with steeper rate of cognitive decline on follow-up but not with baseline cognitive performance. Baseline IL-6 levels and markers of innate and adaptive immune activation showed no relationship with MCI risk or cognitive decline. Conclusion: Inflammation, mediated by TNF signaling, may play a selective role in the early phase of AD. Accordingly, plasma TNFR1 may facilitate improved prediction of disease progression for individuals in the preclinical stage of AD.

KW - biomarkers

KW - cognitive decline

KW - cytokines

KW - inflammation

KW - preclinical AD

KW - TNFR1

UR - http://www.scopus.com/inward/record.url?scp=85072834444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072834444&partnerID=8YFLogxK

U2 - 10.3389/fnagi.2019.00229

DO - 10.3389/fnagi.2019.00229

M3 - Article

C2 - 31555121

AN - SCOPUS:85072834444

VL - 11

JO - Frontiers in Aging Neuroscience

JF - Frontiers in Aging Neuroscience

SN - 1663-4365

M1 - 229

ER -